| Please add [email protected] to your Safe Senders list. If you have trouble viewing this message, click here to view it online. | | |
| In this issue of The Lancet Gastroenterology & Hepatology: |
| Vol.6 Number 6 | Jun 2021 | p 411-510 | e5 |
|
| My Account | Subscribe Now | Authors | About Us | Podcasts |
|
| Editor's Choice | Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial. Read this Article |
| In conversation with: Hugh Thomas, our Deputy Editor, and the journal's authors explore their research and its impact on people's health, health care, and health policy in this regular podcast. Subscribe to this podcast |
|
| |
| | | Obesity: another ongoing pandemic
|
| Infliximab discontinuation in patients with ulcerative colitis
|
| Laparoscopic pancreatoduodenectomy: extensive learning curve, marginal benefits
|
| Affordable treatment and political commitment are crucial to eliminate hepatitis C globally
|
| Optimising clinical trial design to manage placebo response in randomised controlled trials of irritable bowel syndrome
|
| Low-dose aspirin and mesalazine for patients with familial adenomatous polyposis
|
| Irritable bowel syndrome: a spotlight on future research needs
|
| Racial and ethnic disparities in non-alcoholic fatty liver disease in the USA
|
| Impairment of colorectal cancer screening during the COVID-19 pandemic
|
| Impairment of colorectal cancer screening during the COVID-19 pandemic
|
| Correction to Lancet Gastroenterol Hepatol 2021; 6: 482–97
|
| | | | | Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial
|
| Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours: a multicentre, open-label, randomised controlled trial
|
| Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial
Open Access |
| The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis
|
| Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial
|
| Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group
|
| The relationship between gastrointestinal cancers and the microbiota
|
| Enterobius vermicularis infection associated with positive faecal occult blood testing and eosinophilia
|
| |
| Online First | | May 7, 2021 | | Therapeutic targeting of VEGFR2 in HBV-associated hepatocellular carcinoma | |
| May 7, 2021 | | Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial | |
| May 6, 2021 | | Treatment-as-prevention in prison settings: a growing evidence base for HCV elimination efforts | |
| May 6, 2021 | | Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study | |
| May 5, 2021 | | Cuts to UK official development assistance budget jeopardise global viral hepatitis elimination goals | |
| May 4, 2021 | | Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach | |
| April 26, 2021 | | Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis | | Open Access | | | View the full list of Online First articles | |
|
|
|
|
|
You are receiving this email because you subscribed to TheLancet.com alerting service. This email has been sent from The Lancet Gastroenterology & Hepatology, Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, registered in England with registered number 1982084. Update mailing preferences to choose which Lancet journals you receive alerts from. Follow this link to unsubscribe. Privacy Policy Copyright © 2021 Elsevier Limited except certain content provided by third parties. The Lancet is a trade mark of Elsevier Limited. Subscription ID: 22b9c86e-84f2-405a-be9a-05e58abd1b54 Webuser ID: 68907248 Results Event ID: 84c7535c-03ff-4fc5-842f-b2e929f5b599 |
|
|
|
